Recordati

Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
  • TickerREC
  • ISINIT0003828271
  • SectorPharmaceuticals & Biotechnology
  • CountryItaly

Analysts

Recordati – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Fehmi Ben Naamane ...
  • Jerôme Bodin
  • Matthias Desmarais
  • Michael Foundoukidis
  • Oussema Denguir
  • Pierre Tegner
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/12/2019

The major upheavals in the Chinese cement sector could still change the face of a moribund sector, by pushing prices upwards. A trio of Chinese cement manufacturers are serious candidates for acquiring the vestiges of the fallen cement empire, in our view. Partnership projects between Chinese and European groups could lead to cross-shareholdings. We are revising up our cement price forecasts for southeast Asia. HeidelbergCement looks like the big winner from these changes and harbours...

Paola Saglietti

RECORDATI - FY 18 results met guidance and FY 19 guidance confirmed

Fehmi Ben Naamane ...
  • Jerôme Bodin
  • Matthias Desmarais
  • Michael Foundoukidis
  • Oussema Denguir
  • Pierre Tegner
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/02/2019

Après un suspense digne de ‘Borgen’, l’UE a rejeté le projet Alstom + Siemens Mobility. Toutefois Alstom seul est très solide, en croissance et rentable, et pourra rendre du cash aux actionnaires tout en participant à la consolidation du secteur. Notre valorisation du titre est désormais de 42.5 €. - ...

Recordati : Focus Emission

Rossini, the holdco set up by CVC Capital Partners for the acquisition of a controlling stake in Italian specialty pharma Recordati, is issuing an inaugural seven-year € 1.28bn bond split into fixed and floating rate tranches. We think that Recordati has a sound credit profile thanks to a much diversified portfolio of products, therapeutic areas and countries and an excellent track record of growth and margin expansion. The company is active in a variety of drugs, each present in...

Recordati : Issuance Focus

Rossini, the holdco set up by CVC Capital Partners for the acquisition of a controlling stake in Italian specialty pharma Recordati, is issuing an inaugural seven-year € 1.28bn bond split into fixed and floating rate tranches. We think that Recordati has a sound credit profile thanks to a much diversified portfolio of products, therapeutic areas and countries and an excellent track record of growth and margin expansion. The company is active in a variety of drugs, each present in...

Paola Saglietti

RECORDATI - FY 18 results met guidance and FY 19 guidance confirmed

Oussema Denguir ...
  • Pierre Corby

Recordati : Back in the rare diseases game in 2019?

>2018 results in line with expectations - Recordati reported its preliminary FY 2018 results midday yesterday. Contract fulfilled for management which reported figures in line with and even slightly better than guidance. The reported figures are in line with our expectations and those of the consensus: sales of € 1,352m (+5%), EBITDA of € 499m (+10%), EBIT of € 442m (+9%) and net profit of € 312m (+8%). Net debt reached € 588m, up € 200m (€ 382m at end-December 2017) ...

Oussema Denguir ...
  • Pierre Corby

Recordati : Back in the rare diseases game in 2019 ?

>Résultats 2018 en ligne avec les attentes - Hier à la mi-journée, Recordati a publié ses résultats préliminaires FY 2018. Contrat rempli pour le management qui publie des chiffres conformes à la guidance voire légèrement mieux que cette dernière. Les chiffres publiés ressortent en ligne avec nos attentes et celles du consensus : des ventes de 1 352 M€ (+5%), un EBITDA de 499 M€ (+10%), un EBIT de 442 M€ (+9%) et un RN de 312 M€ (+8%). La dette nette ressort à 588 M€ ...

Pierre Corby ...
  • Team Pharma

Roche Holding : A first sign of vertical consolidation in the US?

>Amgen and Magellan Rx (PBM) announce agreement on a number of chronic diseases - Amgen and Magellan Rx, a PBM (Pharmacy Benefit Manager), announced at the start of the week a multi-year agreement to improve clinical outcomes for patients with osteoporosis and migraine. This is Amgen's first collaboration with a PBM. Amgen says the partnership is part of a commitment to improve patient health while lowering costs (in a context of price pressure). In cases of osteoporo...

Pierre Corby ...
  • Team Pharma

Roche Holding : Un premier signe de consolidation verticale aux Etats-Unis ?

>Amgen et Magellan Rx (PBM) annoncent un accord dans certaines maladies chroniques - Amgen et Magellan Rx, un PBM (Pharmacy Benefit Manager), ont annoncé en début de semaine un accord pluriannuel visant à améliorer les résultats cliniques pour les patients atteints d’ostéoporose et de migraine. Il s’agit de la première collaboration d’Amgen avec un PBM. Amgen indique que ce partenariat s’inscrit dans une volonté d’améliorer la santé des patients tout en abaissant les ...

A director bought 16,000 shares at 30.250EUR and

A director at Recordati bought 16,000 shares at 30.250EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Fehmi Ben Naamane ...
  • Jerôme Bodin
  • Matthias Desmarais
  • Michael Foundoukidis
  • Oussema Denguir
  • Pierre Tegner
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/12/2019

The major upheavals in the Chinese cement sector could still change the face of a moribund sector, by pushing prices upwards. A trio of Chinese cement manufacturers are serious candidates for acquiring the vestiges of the fallen cement empire, in our view. Partnership projects between Chinese and European groups could lead to cross-shareholdings. We are revising up our cement price forecasts for southeast Asia. HeidelbergCement looks like the big winner from these changes and harbours...

Fehmi Ben Naamane ...
  • Jerôme Bodin
  • Matthias Desmarais
  • Michael Foundoukidis
  • Oussema Denguir
  • Pierre Tegner
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/02/2019

Après un suspense digne de ‘Borgen’, l’UE a rejeté le projet Alstom + Siemens Mobility. Toutefois Alstom seul est très solide, en croissance et rentable, et pourra rendre du cash aux actionnaires tout en participant à la consolidation du secteur. Notre valorisation du titre est désormais de 42.5 €. - ...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/12/2018

...

Ahmed Ben Salem ...
  • Alex Koagne
  • Alexandre Iatrides
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Nicolas David
  • Olfa Taamallah
  • Oussema Denguir
  • Philippe Ourpatian
  • Pierre Tegner
  • Pierre Corby
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/31/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Recordati – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Jérôme VINERIER

Short term view - RECORDATI IND CHI : The trend is bearish.

The trend is bearish. The bounce is gaining strength. The bounce might end at the resistance at €31.20 and prices would fall again toward €27.10. The background trend would be questioned should prices rise above €35.30.

Jérôme VINERIER

Analyse court terme - RECORDATI IND CHI : La tendance est baissière.

La tendance est baissière. Le rebond gagne en vigueur. Il est probable que cette reprise s'achève sur la résistance à 31,20 € et que les prix baissent à nouveau vers 27,10 €. La tendance de fond serait remise en cause en cas de franchissement de 35,30 €.

Jérôme VINERIER

Short term view - RECORDATI IND CHI : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €31.20 and then €33.00. The break of €27.10 would endanger the trend.

Jérôme VINERIER

Analyse court terme - RECORDATI IND CHI : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 31,20 € puis 33,00 €. La rupture de 27,10 € mettrait la tendance en danger.

Valérie GASTALDY

Medium term view - RECORDATI IND CHI : Overbought stochastics

The trend is uncertain. Stochastics are at the overbought level. prices could fall again to €27.71.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch